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ABSTRACT  19 
Synapses compute and transmit information to connect neural circuits and are at the basis of brain 20 
operations. Alterations in their function contribute to a vast range of neuropsychiatric and 21 
neurodegenerative disorders and synapse-based therapeutic intervention, such as selective 22 
inhibition of synaptic transmission, may significantly help against serious pathologies. Graphene 23 
is a two-dimensional nanomaterial largely exploited in multiple domains of science and 24 
technology, including biomedical applications. In hippocampal neurons in culture, small graphene 25 
oxide nanosheets (s-GO) selectively depress glutamatergic activity without altering cell viability. 26 
Glutamate is the main excitatory neurotransmitter in the central nervous system and growing 27 
evidence suggests its involvement in neuropsychiatric disorders. Here we demonstrate that s-GO 28 
directly targets the release of pre-synaptic vesicle. We propose that s-GO flakes reduce the 29 
availability of transmitter, via promoting its fast release and subsequent depletion, leading to a 30 
decline of glutamatergic neurotransmission. We injected s-GO in the hippocampus in vivo, and 31 
forty-eight hours after surgery ex vivo patch-clamp recordings from brain slices show a significant 32 
reduction in glutamatergic synaptic activity, in respect to saline injections. 33 
 34 
 35 
 36 
 37 
 38 
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Graphene is a 2D material made of sp2-hybridized carbon atoms organized in a hexagonal lattice 39 
and characterized by excellent physical features, including outstanding electron mobility and 40 
mechanical flexibility.1-3 Because of its properties,4-6 graphene is considered a rising star in a 41 
growing number of technological developments, including biomedical ones.2,4,5,7 In neurology, 42 
graphene–based neuronal implants or bio-devices, may overcome current technical limitations in 43 
treating pathologies that range from neurooncology to neuroregeneration.8,9 We reported recently 44 
the ability of small, thin graphene oxide sheets (s-GO) to alter specifically neuronal synapses, with 45 
no impact on cell viability. In particular, in cultured hippocampal networks, upon chronic long-46 
term exposure to s-GO, glutamatergic release sites were sized down.10 It is well known that 47 
glutamate is the main excitatory neurotransmitter in the mammalian central nervous system (CNS) 48 
and mediates neuronal development, migration, synaptic maintenance and transmission.11-13 An 49 
uncontrolled release of glutamate in the extracellular space may lead to excitotoxicity, 50 
neurodegeneration and neurological disorders, including pain.14 Localized targeting and fine-51 
tuning of the glutamatergic system are attractive objectives in neuroscience. To achieve a deep 52 
understanding of the interactions between s-GO and the machinery governing nerve cell functions 53 
is mandatory to translate these findings into potential therapeutic applications. In particular, 54 
graphene translocation or adhesion to cell membranes15,16 may potentially interfere with activities 55 
such as the exocytic and endocytic trafficking systems, essential to physiological synaptic 56 
transmission.15,17 Here, we describe, by single cell electrophysiology, how s-GO nanosheets 57 
acutely tune synaptic release in excitatory synapses of hippocampal cultured neurons and acute 58 
slices, by interfering with the probability of vesicle release. We propose that such interference 59 
leads to transmitter depletion and subsequent depression of the glutamatergic activity. We next 60 
address whether such material similarly affects glutamatergic transmission in vivo, by injecting s-61 
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GO in the dentate gyrus of the hippocampus of juvenile rats. We patch-clamped single neurons 62 
from ex vivo hippocampal slices, 48 h and 72 h after s-GO microinjections. We demonstrate that 63 
s-GO targets and down-regulates glutamatergic synapses in vivo and further illustrates the 64 
potential of s-GO flakes to be engineered as specific synaptic transmission modulators. 65 
GO functionalization and characterization. The produced s-GO dispersion was visually 66 
homogenous and of a brownish-translucent appearance. The dispersions did not show any evidence 67 
of sedimentation or any other observable changes for over 6 months, indicating their physical 68 
stability. The characterization of the s-GO nanosheets is presented in Figure 1 and in 69 
Supplementary Figure S1. The morphological features of the s-GO nanosheets were examined 70 
using AFM (Figure 1a) and TEM (Supplementary Figure S1a). Both analytical methods showed 71 
that the lateral dimension of the s-GO nanosheets was predominantly between 100–300 nm with 72 
very few larger sheets into the μm range (Figure 1b). Moreover, AFM revealed that the material is 73 
composed of sheets from single to few-layer thickness (Supplementary Figure S1b). The material 74 
structural features were studied by Raman spectroscopy which evidenced the presence of the 75 
characteristic G and D scatter bands at 1595 cm−1 and 1330 cm-1, respectively (Figure 1c). The D 76 
scatter band was markedly higher than the G band. The intensity ratio of these two peaks, known 77 
as the I(D)/ I(G), was calculated to be 1.31 ± 0.01, indicating that the material hexagonal lattice 78 
was defected. XPS analysis corroborated to the presence of functional groups (Supplementary 79 
Figure S1c) and further indicated that the defects correspond to oxygen-containing functionalities. 80 
The C/O ratio was found to be 2.1 and the material chemical purity was 99.8 %.18 The surface 81 
functionalization was further supported by laser Doppler electrophoresis to indicate that the 82 
dispersed sheets had a surface charge of -55.9 ± 1.4 mV. Aiming to track the s-GO flakes within 83 
neuronal tissue we performed covalent labeling of s-GO with quantum dot (QD) luminescent 84 
nl-2018-04903jR2 
 5 
nanoparticles. For this purpose, we first synthetized the AgInS2/ZnS-doped QDs capped with 85 
cysteine as described in the literature (see TEM images in Supplementary Figure S1d).19,20 86 
Subsequently, the coupling with s-GO was achieved via epoxy ring opening with the amino groups 87 
of the cysteine-capping agent. TEM microscopy shows the presence of small dark dots on the s-88 
GO sheets associated with the presence of QDs on the surface (Supplementary Figure S1e, 89 
indicated by the arrows) as confirmed by XPS survey analysis (Figure 1d). The UV-Vis spectrum 90 
(Figure 1e) of the functionalized material showed a broadening of the absorption band between 91 
300 and 600 nm due to the presence of the nanocrystals onto GO. Fluorescence characterization is 92 
reported in Figure 1f; s-GO showed an emission centered at 585 nm attributed to the electronic 93 
transitions from the bottom of conductive band and the nearby localized states to the valence 94 
band.21 QDs have an emission centered at 706 nm due to transition between the conductive band 95 
and the defected carbon lattice.22 Interestingly, when QD were coupled to graphene oxide only s-96 
GO luminescence was detected. The quenching of the QD emission may be attributed to an 97 
interfacial electron transfer between the QDs and the s-GO surface due to their close proximity.23,24 98 
Surprisingly, the emission band centered at 585 nm, attributed to the GO photoluminescence, 99 
appeared stronger in the case of QD-s-GO than in non-modified s-GO. Most probably, the energy 100 
transfer process causes the decrease of donor emission (QD quenching) and increase the s-GO 101 
acceptor emission24 allowing us to visualize the s-GO-QD in the biological environment (vide 102 
infra). 103 
s-GO targets synaptic vesicle release at glutamatergic synapses in cultured hippocampal 104 
neurons. To unravel the mechanisms by which thin s-GO sheets affect neurotransmission, we 105 
patch-clamped cultured hippocampal neurons while a second pipette for the local delivery of 106 
standard saline solution of s-GO (100 μg/mL; see Methods) was positioned at 200 μm distance (by 107 
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microscopic guidance) from the recorded neuron (sketched in Figure 2a). We estimated that, at 108 
this distance, the application of a brief (500 ms) pulse of pressure should result in a local (i.e. on 109 
the patched cell) and transient delivery of s-GO at a concentration of at least 10 % of that contained 110 
in the pipette (see Methods). Spontaneous synaptic activity was recorded in the presence of 111 
Tetrodotoxin, (TTX; 1 μM). In TTX, synaptic events, termed miniature post synaptic currents 112 
(mPSCs), reflect the pre-synaptic, stochastic release of vesicles at individual synaptic terminals 113 
impinging on the recorded neuron. mPSCs frequency reflects the pre-synaptic release probability 114 
and on the number of synaptic contacts, while mPSCs amplitude is dictated by postsynaptic 115 
receptor sensitivity.25 Baseline mPSCs were sampled before and after the local ejection of saline 116 
or s-GO (Figure 2b). In cultured neurons, virtually all mPSCs were made up by excitatory (AMPA 117 
glutamate receptor-mediated) events, identified by their fast kinetics (decay time constant τ = 5 ± 118 
0.5 ms;26), and were thus named excitatory mPSCs (mEPSCs). Figure 2b shows representative 119 
control (top) and s-GO (bottom) current tracings prior and after saline or s-GO solution, 120 
respectively, were pressure ejected. In control neurons mEPSCs frequency did not change (from 121 
0.06 ± 0.03 Hz to 0.065 ± 0.04 Hz after saline-ejection, n = 14; bar plot in Figure 2c, left). On the 122 
contrary, acute s-GO ejection significantly increased (* P < 0.05 Student’s t-test) the mEPSCs 123 
frequency (from 0.04 ± 0.01 Hz to 0.12 ± 0.02, n = 13; bar plot in Figure 2c, left). The increase in 124 
mEPSCs appeared with 8-10 s delay from the local s-GO ejection and completely reversed to 125 
baseline values (0.04 ± 0.01 Hz) 8-9 min following the acute application (bar plot in Figure 2c, 126 
left). In all treatments, the mEPSCs amplitude was not affected (bar plot in Figure 2c, right). These 127 
transient changes in the frequency of mEPSCs suggest a direct interference of s-GO with the 128 
presynaptic release machinery27,28 and are consistent with the hypothesized targeting by s-GOs of 129 
endo-exocytotic mechanisms. This hypothesis is also validated by the co-localization of bassoon 130 
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(pre-synaptic terminal marker29) and s-GO detected by confocal microscopy in a different set of 131 
experiments, where s-GO was incubated (20 μg/mL; 30 min), before fixation of the cultures (see 132 
Methods; Supplementary Figure S2 a and b, controls and s-GO, respectively). We further address 133 
the dependency of these effects on the flakes’ size. We adopted the same protocol to press-eject 134 
GO flakes (same concentration as s-GO) characterized by different lateral dimensions: large GO 135 
(l-GO, ≈ 2 μm) or ultra-small GO (us-GO, ≈ 40 nm).18 Supplementary Figure S2 c shows 136 
representative control (top) and l-GO (bottom) current tracings sampled before and after the local 137 
ejection of saline or l-GO solutions. Opposite to s-GO, l-GO did not change mEPSCs frequency 138 
(from 0.06 ± 0.01 Hz to 0.07 ± 0.02 HZ after saline ejection, n = 5; from 0.05 ± 0.01 Hz to 0.07 ± 139 
0.02 Hz after l-GO ejection, n = 5). Similarly (Supplementary Figure S2 d), us-GO did not 140 
modulate mEPSCs frequency (from 0.05 ± 0.01 Hz to 0.07 ± 0.02 Hz, after saline. n = 8 and from 141 
0.05 ± 0.01 Hz to 0.07 ± 0.02 Hz, after us-GO, n = 8).  142 
Thus only s-GO transiently increased the frequency of mEPSCs. This apparent discrepancy with 143 
our previous results, where prolonged exposure to s-GO decreased glutamatergic activity,10 may 144 
be explained by the emergence of glutamate depletion due to forced glutamate release. The latter 145 
leading to a transient facilitation followed, when s-GO is applied longer than the duration of the 146 
facilitatory effects, by a depression of vesicle release and thus a down-regulation of glutamate 147 
transmission.10 148 
To investigate the s-GO interference with presynaptic release and whether this was truly selective 149 
for excitatory synapses, we tested the local delivery of s-GO nanosheets on the occurrence of 150 
evoked PSCs (ePSCs), by simultaneous whole-cell recordings from two monosynaptically 151 
connected neurons.26 Action potentials were induced in the presynaptic neuron and the evoked 152 
postsynaptic unitary PSCs (delay 2 ms) were examined. In our in vitro system, monosynaptically 153 
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coupled pairs of neurons typically display either GABAA or glutamate AMPA receptor-mediated 154 
evoked currents.26,30,31 We identified the different populations of ePSCs on the basis of their kinetic 155 
properties and pharmacology.26,32 In fact, GABAergic ePSCs were characterized by a slow decay 156 
time constant (τ = 23 ± 7 ms, n = 15 for each condition, control and s-GO; Figure 2d, left) and 157 
were fully abolished by administration of 5 μM Gabazine (n = 3). Glutamatergic AMPA receptor–158 
mediated ePSCs displayed fast decay (τ = 7 ± 1.2 ms, n = 7 for each condition; Figure 2d, right) 159 
and were further blocked by application of 10 μM CNQX (n = 3). To investigate the presynaptic 160 
properties we adopted paired-pulse stimulation protocols.33,34 In paired-pulse stimulation the 161 
second response can be either facilitated or depressed. Usually, at a specific synapse, an increased 162 
probability of neurotransmitter release will favor paired-pulse depression, while a decrease in the 163 
release probability favors facilitation.33,35,36 Thus, differences in postsynaptic responses to paired-164 
pulse stimulation indicate variations in presynaptic transmitter release.33,36-38 To probe the changes 165 
in efficacy of unitary ePSCs paired-pulse protocols were performed with short inter-stimulus 166 
interval (50 ms). Figure 2d shows representative presynaptic pairs of action potentials (top) and 167 
the corresponding monosynaptic GABAergic (left tracings) or glutamatergic AMPA receptor 168 
(right) evoked currents (bottom) before and after s-GO local pressure ejection. We indirectly 169 
assessed the GABA and glutamate release probability before and after saline (control) or s-GO 170 
ejection by measuring the paired-pulse ratio (PPR, calculating the ratio between the mean peak 171 
amplitude of the second and the first PSC37,38). In control GABAergic and glutamatergic ePSCs 172 
the resulting PPR indicated the presence of paired pulse depression and did not change upon saline 173 
solution applications (for GABAA receptor-mediated pairs: 0.5 ± 0.2 before and 0.6 ± 0.2 after 174 
saline; for AMPA receptor-mediated pairs: 0.5 ± 0.1 before and 0.6 ± 0.2 after saline, plot in Figure 175 
2d). When investigating the impact of s-GO ejection, we detected a reduction (on average − 32 %) 176 
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in the amplitude of the first glutamatergic ePSC and a significant difference (* P < 0.05 Student’s 177 
t-test) in PPR, indicative of paired-pulse facilitation, while the PPR did not change in GABAA 178 
ePSCs (for AMPA mediated pairs: 0.5 ± 0.1 before and 2 ± 0.9 after s-GO; for GABAA mediated 179 
pairs: 0.5 ± 0.2 before and 0.65 ± 0.2 after s-GO; summarized in the bar plots in Figure 2d, bottom). 180 
Altogether these experiments strongly support a direct interference of s-GO flakes with synaptic 181 
vesicle release, with an initial high rate of release followed by a decline when s-GOs are applied 182 
longer10 or when acting synergistically to the action potential-evoked activation of the exocytotic 183 
apparatus, ultimately depleting evoked release, typically reflected by changes in ePSC 184 
amplitude.39,40 Notably, only glutamatergic synapses were targets of the s-GO.  185 
s-GO exposure specifically affects glutamatergic synapses in acute hippocampal slices. Since 186 
cultured networks are simplified 2D models of immature brain circuits, we explored the ability of 187 
s-GO to regulate glutamate synaptic activity in acute hippocampal slices, thus scaling up the 188 
complexity of the tissue to the third dimension and testing more mature synapses. Single neuron 189 
patch-clamp recordings were obtained from visually identified pyramidal cells in the CA1 190 
hippocampal region. A second pipette was again positioned at a distance of 200 μm from the 191 
recorded cell (sketched in Figure 3a) and filled with standard saline solution or with s-GO (100 192 
μg/mL). Baseline PSCs were recorded before and after the local saline or s-GO ejection. Figure 193 
3b shows representative current tracings of controls (top) and s-GO (bottom) before and after 194 
saline or s-GO solutions, respectively, were pressure ejected. In neurons exposed to saline solution, 195 
spontaneous PSCs frequency did not change (6 ± 2 Hz before the pipette saline-ejection and 5 ± 1 196 
Hz after the pipette saline-ejection, n = 14). On the contrary, acute s-GO ejection significantly 197 
increased (* P < 0.05 Student’s t-test) the PSCs frequency (from a baseline of 5 ± 2 Hz to a post 198 
ejection frequency of 8 ± 2 Hz, n = 13). The increase in PSCs after the local s-GO ejection was 199 
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reversible. In fact, PSC frequency fully returned to baseline values 7-8 min following the acute 200 
application. In all treatments, the PSC amplitude was not affected. We further dissected the nature 201 
of PSCs by the use of CNQX or Gabazine, isolating GABAA or AMPA receptor-mediated IPSCs 202 
or EPSCs, respectively. When EPSCs were measured after s-GO ejection, we detected a strong 203 
increase (* P < 0.05 Student’s t-test) in their frequency when compared to the saline solution 204 
pressure application (4 ± 1 Hz before and 4.7 ± 1 Hz after the pipette saline-ejection; 4.2 ± 0.9 Hz 205 
before and 7.3 ± 1 Hz after the s-GO ejection, Figure 3c). On the contrary, when we measured 206 
IPSCs, their frequency was not affected both by saline (4.2 ± 1 Hz before and 4.8 ± 1 Hz after, 207 
Figure 3d) and s-GO (3.8 ± 1 Hz before and 4.2 ± 1 Hz after, Figure 3d) pressure applications. 208 
Such results support the notion of s-GO ability to specifically target excitatory synapses, even in 209 
tissue explants. In cultured neurons as well as in acute hippocampal slices, the brief pressure 210 
ejection of s-GO transiently increased the excitatory activity, apparently affecting glutamate 211 
release machinery at the presynaptic site.  212 
To ascertain whether prolonged interference of s-GO with excitatory synapses might indeed 213 
reduce the activity of synapses capable of releasing glutamate, as observed in dissociated cultures10 214 
we incubated acute slices with s-GO (50 µg/mL) and we monitored PSCs frequency after 30 min 215 
(n = 5), 45 min (n = 5), 3 h (n = 5) and 6 h (n = 8).  Under these experimental conditions, s-GO 216 
will be repeatedly presented at synapses, in the absence of the fast clearance brought about by 217 
saline flow rate in the previous experiments (see Methods). The plots in Figure 3e compare the 218 
frequencies of PSCs in Control and s-GO treated samples against 4 different exposure time points. 219 
A progressive reduction in PSCs frequency was observed from 30 min to 6 h (from 5.8 ± 1 Hz to 220 
3.6 ± 0.8 Hz), such changes were not detected in control (from 5.0 ± 1 Hz to 5.3 ± 1 Hz). In Figure 221 
3e, by linear regression analysis of the two time progressions (Control and s-GO) combined to 222 
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multiple regression statistical analysis, we show that the zero slope hypothesis is accepted for 223 
Controls but not for s-GO, indicative of a significant progressive decrease in PSCs frequencies due 224 
to s-GO prolonged incubation.  225 
In vivo intra-hippocampal s-GO delivery reversibly reduces glutamatergic synaptic activity 226 
in juvenile rats with minimal tissue reaction. To gain more insights into the synapse specificity, 227 
tissue reactivity and kinetics of s-GO in vivo, we injected in juvenile rats (P15) 1 µL of s-GO (50 228 
µg/mL in saline solution; Figure 3f) in the dentate gyrus of the hippocampus and we patch-clamped 229 
single neurons to measure glutamatergic synaptic activity from ex vivo hippocampal slices isolated 230 
after 48 h and 72 h after the brain surgeries. As control, we injected 1 µL of saline solution in the 231 
same anatomical region. Figure 3f shows representative current tracings of the recorded electrical 232 
activity in acute slices isolated from the contralateral (not subjected to the injection), the control 233 
saline- and s-GO-injected hemispheres, after 48 h from injection. After this time period 234 
hippocampal slices isolated from s-GO treated animals showed a clear and significant (** P < 0.01 235 
two-way ANOVA) reduction in PSCs frequency (2 ± 0.5 Hz, n = 7), when compared with slices 236 
from the contralateral untreated hemisphere (5 ± 1 Hz, n = 9) or with saline treated ones (4.3 ± 1 237 
Hz, n = 8; see plot in Figure 3g). Remarkably, such effects were reversible: upon 72 h recovery 238 
post injections the reduction in synaptic PSCs frequency in s-GO treated slices is absent (6 ± 1.3 239 
Hz, n = 8 for contralateral slices; 5.7 ± 1.5 Hz, n = 7 for saline-injected slices; 6.2 ± 1.8 Hz, n = 7 240 
for s-GO-injected slices; see plot in Figure 3g). In all treatments, the PSCs amplitude was not 241 
affected. When pharmacologically discriminating GABAA and AMPA receptor-mediated PSCs, 242 
we specifically detected after 48 h of s-GO a significant (* P < 0.05 two-way ANOVA) reduction 243 
in EPSCs frequency (2.9 ± 0.8 Hz, n = 7), when compared with slices from the contralateral 244 
untreated hemisphere (4.8 ± 1 Hz, n = 9) or with saline treated ones (5 ± 1.3 Hz, n = 8; see right 245 
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plot in Figure 3h). GABAA receptor-mediated PSCs where not affected by any treatment (from 3.5 246 
± 1 Hz to 3.9 ± 0.8 Hz after saline-ejection, n = 8, and from 3 ± 0.5 Hz to 3.4 ± 0.5 Hz after s-GO-247 
ejection; n = 7). To prove the presence of s-GO and gain more insight regarding its fate within the 248 
hippocampus in vivo, we used bright field microscopy with correlative Raman based mapping 249 
(Figure 4a). Forty-eight h following intra-hippocampal delivery (50 μg/mL final concentration; 1 250 
μL injected volume), the presence of s-GO could be positively identified within the 20 μm sections 251 
of injected hippocampi, specifically within the confines of the dentate gyrus. However, 72 h post 252 
injection, the material presence is shown to decrease. We also tested the hippocampi of rats that 253 
were injected with a saline control and a higher concentration of s-GO (1.3 mg/mL; 1 μL), which 254 
served as negative and positive controls, respectively, to verify our data. The localization of s-GO 255 
by using QD-s-GO (50 μg/mL; 1 μL) was performed next. Figure 4b shows the 256 
immunofluorescence labeling of slices isolated from the treated hippocampus where the area of 257 
injection is highlighted by the typical microglia reaction (Iba1 positive cells in green) due to the 258 
surgery per se.41,42 QD-s-GO was typically localized in the area of injection after 24 h (red 259 
staining). Next we investigated whether s-GO injection was affecting the number of synapses in 260 
the injected brain area. We used bassoon marker for pre-synaptic terminals present in both 261 
glutamatergic and GABAergic synapses.29 We quantified the co-localization of bassoon with 262 
neurons (labeled with β-tubulin III) and we did not detect any difference between saline and s-GO 263 
treated (48 h) animals in terms of bassoon volume at the injection site (saline 552.68 ± 155.06 µm3 264 
and s-GO 570.40 ± 115.74 µm3; number of animals = 2 for each experimental group; Figure 4c,d). 265 
To investigate tissue reactivity, in particular neuroglia responses, to s-GO following 48 h and 72 266 
h, we performed immunohistochemistry experiments on treated animals to identify GFAP-positive 267 
astrocyte and Iba1-positive microglia (number of animals = 3 for each experimental group; Figure 268 
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5a,b). We measured astrocytes and microglia located 300 µm apart to the injection site in the 269 
medial and lateral directions, at such a distance we detected only a low tissue response in all groups 270 
(Figure 5c,d). Conversely, at the injection site the tissue reactivity was higher, as expected,41,42 yet 271 
comparable between saline and s-GO. To note, astrocyte recruitment was decreased in s-GO 272 
treated animals, particularly after 48 h; while microglia reactivity was similar in saline and s-GO 273 
groups after 48 h, but it was significantly lower in s-GO treated animals after 72 h (Figure 5; ** 274 
P<0.01; two-way ANOVA).  275 
We report here the ability of s-GO nanosheets to interact selectively with glutamatergic synapses, 276 
affecting the efficacy of neurotransmission, in vitro and in vivo. In particular, in cultured 277 
hippocampal neurons, brief exposures to s-GO promote an initial high rate of glutamate quantal 278 
release, presumably by modifications at the pre-synaptic site, as indicated by the increase in 279 
frequency of spontaneous mEPSCs25,43,44 and by the paired-pulse experiments.33,35-38 We 280 
hypothesize that this initial high rate of release depletes presynaptic glutamate and, in the 281 
continuous presence of s-GO, inhibit glutamatergic transmission. Indeed, in the same preparation, 282 
the decline in action potential-evoked monosynaptic EPSCs upon s-GO exposure supports the 283 
notion of a subsequent reduction in the probability of release following vesicle depletion45 brought 284 
about by s-GO. In all tests, the mere pressure ejection of saline solution without s-GO, or GO of 285 
different dimensions, did not change spontaneous or evoked synaptic responses. Notably, 286 
GABAergic synapses were never affected. The bi-phasic effects of s-GO, characterized first by a 287 
transient increase in neurotransmitter release which, upon a potential reduction in the vesicle-pool 288 
size, is followed by a depression, hints at the ability of s-GO to engage the presynaptic exocytotic 289 
machinery, as also supported by the co-localization with pre synaptic terminal markers. 290 
Neurotransmitter release, at the presynaptic site in the CNS, is controlled by specific proteins that 291 
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function in large complexes, displaying multiple roles in synaptic vesicle recycling.46 In addition 292 
to release-proteins another potential target of s-GO is represented by intracellular Ca2+ levels, 293 
known to regulate evoked neurotransmitter release45 and recently reported to be modulated by 294 
chronic exposure to s-GO.47 Although we cannot exclude a role of presynaptic Ca2+ influx 295 
contributing to acute s-GO effects, the detected increase in spontaneous miniature current 296 
frequency, much less dependent on Ca2+ levels,44,48 and the absence of modulation by s-GO of the 297 
GABAergic terminals, usually regulated by presynaptic Ca2+ dynamics49, are suggestive of a Ca2+ 298 
independent mechanisms. The responses evoked by pressure ejected s-GO are reminiscent to those 299 
induced by hypertonic solutions50, however a simple osmotic mechanism is ruled out by the 300 
selectivity of the effects (restricted to glutamatergic terminals) observed in all conditions tested 301 
and by direct osmotic pressure measures (see Methods). The current data are in agreement with 302 
our previous report, where a long-term (days) exposure to s-GO selectively down regulated 303 
excitatory neurotransmission leaving inhibitory synapses unchanged.10 We previously 304 
speculated10 that differences in GABAergic and glutamatergic synaptic cleft ultrastructure, in 305 
particular in the cleft size and organization51, might explain why the latter terminals became ideal 306 
targets to s-GO interactions. To note, larger or smaller GO flakes did not modulate glutamate-307 
mediated synaptic transmission. In this framework, we propose a simply mechanistic interpretation 308 
of our current experiments: glutamatergic synapses, in virtue of their relatively larger size and less 309 
structured organization,51 allow penetration of s-GO flakes which remain trapped within the cleft 310 
and adhere to the plasma membrane at active release sites. GO nanosheets have been suggested to 311 
adhere to complex patches of cellular membranes, rather than specific ones.52 Also in our 312 
experiments, the s-GO adhesion to the membrane may be supported by non-specific interactions 313 
(as described in other cell types52) accompanied by variable degrees of membrane deformations, a 314 
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mechanism further supported by our previous results showing astrocyte vesicle shedding when 315 
exposed to s-GO.10 A deformation of synaptic active zones would interfere with the exocytosis 316 
and neurotransmitter vesicle release by a mechanical mechanism reminiscent of, for example, 317 
stress induced ones,50 not necessarily implying an impairment of membrane integrity. In fact, we 318 
never observed any functional sign of membrane damage, and in addition the alterations in vesicle 319 
release were reversible. An alternative mechanism, due to the physical properties of nanoparticles, 320 
is related to their surface potential, able to tune neuronal excitability.53 We previously documented 321 
that the s-GO surface potential, measured as zeta potential value10, is negative (− 50 mV), thus the 322 
negative charge may favor the s-GO interactions with neuronal membrane influencing the 323 
excitability of neurons.53 Although we cannot exclude this mechanism, the short- and long- term 324 
regulation and the selectivity for excitatory synapses are not explained by this interpretation. The 325 
interface between dispersed s-GO sheets and the cell membrane is currently subject to active 326 
investigation, due to its potential in modulating cellular mechanosensing for diverse biomedical 327 
applications, nevertheless the nature of such interactions is still elusive.52,54 Synaptic vesicle 328 
recycling machinery represents a feasible therapeutic target, regardless of the direct involvement 329 
of presynaptic function in a pathological process. Even subtle alterations in (pre)-synaptic 330 
communication hold the potential to compensate for deficits without interfering with postsynaptic 331 
signaling. Pre-synaptically targeted drug development might be challenging due to the 332 
sophisticated molecular complexity of the release machinery. The ability of s-GO to specifically 333 
hook glutamatergic presynaptic nerve terminals is thus highly promising, however conventional 334 
2D cultures may lack appropriate cell-extracellular matrix interactions, providing an artificially 335 
higher access of exogenous agents to synapses. s-GO specificity towards glutamatergic synapses 336 
may be virtually restricted to 2D bio-system models. This potential pitfall is excluded by our 337 
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experiments on acute hippocampal slices, the neuroscientist gold standard to investigate synaptic 338 
functions in intact circuitries. The selective effect of s-GO on glutamatergic transmission is 339 
preserved in tissue slices, where excitatory EPSCs are reversibly affected by s-GO, with a short-340 
term up-regulation of release, turned into a down regulation upon prolonged exposure. The 341 
ultimate potential of any s-GO sheets in the design of therapeutic strategies based on synaptic 342 
targeting resides in testing their efficacy in vivo. We demonstrated the delivery of s-GO in vivo 343 
by stereotactic injection and we have shown that such an administration of s-GO (but not the 344 
surgery per se) in the hippocampus of juvenile rats significantly and selectively sized down 345 
glutamatergic activity, in the absence of direct reduction in the number of synapses. We have also 346 
shown that local tissue responses to stereotactic injections41,42 were not increased by the presence 347 
of s-GO in terms of patterns of microglia together with astrocyte aggregation at the injection site. 348 
These results are supportive of, within the concentrations tested, the in vivo biocompatibility of 349 
the s-GO dispersions. In general, GO is characterized by better biocompatibility when compared 350 
to other types of graphene (such as pristine graphene or reduced GO) and additional 351 
functionalization might even further reduce the risk of inflammation and subsequent tissue 352 
toxicity.55 Interestingly, our results also suggest a possible anti-inflammatory effect by limiting the 353 
aggregation of astrocytes surrounding the stereotactic injection and lessening prolonged microglia 354 
reactivity.41,42 This result, although preliminary, is in accordance with previous observations56 and 355 
renders further investigation. Exploiting s-GO in pre-synaptic drug design development certainly 356 
requires additional studies, as well as to ascertain a more precise s-GO mechanism of action and 357 
clearance, since in our experiments, due to diffusion, perfusion flow rate in vitro, potential 358 
membrane recycling,57 and microglial uptake58 we probably had only a “local” tissue clearance.  359 
Besides, most of the studies evaluating the clearance in vivo of GO suggested that GO is rapidly 360 
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cleared, but have been performed in non-mammalian organisms.59,60 In our proof-of-concept in 361 
vivo study the coherence between the low detection of residual s-GO at 72 h and the reversibility 362 
of the synaptic silencing upon 72 h are supportive of a direct, mechanical interaction at the pre-363 
synaptic plasma membrane.  364 
Methods  365 
Graphene oxide nanosheets synthesis. GO was manufactured under endotoxin-free conditions 366 
through our modified Hummers’ method as previously described.10,61 Briefly in this procedure, 0.8 367 
g of graphite flakes was added to 0.4 g of sodium nitrate (Sigma-Aldrich, UK). This was next 368 
followed by the slow addition of 18.4 mL of sulfuric acid 99.999% (Sigma-Aldrich, UK). After a 369 
homogenized mixture was achieved through stirring, 2.4 g of potassium permanganate (Sigma-370 
Aldrich, UK) were added and maintained for 30 min. Thereafter, 37 mL of water for injection 371 
(Fresenius Kabi, UK) were added. This resulted in an exothermic reaction. The temperature was 372 
strictly kept at 98 °C for 30 min. The mixture was next diluted with 112 mL of water for injection 373 
(Fresenius Kabi, UK). Twelve mL of 30% hydrogen peroxide (Sigma-Aldrich, UK) were then 374 
added to reduce the residual KMnO4, MnO2, and MnO7 to soluble manganese sulphate salts. The 375 
resulting mixture purified by repeated centrifugation cycles at 9000 rpm for 20 min until an 376 
orange/brown gel-like layer of GO began to appear on at the pellet-supernatant interface which 377 
occurred at around pH 6-7. This layer was carefully extracted with warm water for injection 378 
(Fresenius Kabi, UK). This layer contained large GO sheets; the obtained material was diluted in 379 
water for injection to yield an aqueous suspension with a concentration of 2 mg/mL. A portion of 380 
this obtained material was then lyophilised, reconstituted in water for injection (Fresenius Kabi, 381 
UK) and then sonicated in a bath sonicator (VWR, 80W) for 5 min. The resulting dispersion was 382 
then centrifuged at 13000 rpm for 5 min at room temperature (RT); the supernatant which 383 
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contained the desired s-GO nanosheets was separated from the unwanted pellet. A thorough 384 
physico-chemical characterization of us-GO and l-GO has already been reported.18 Structural 385 
properties such as lateral dimension and thickness of the GO materials were then studied by AFM 386 
and TEM. Raman spectroscopy and ζ-potential measurements were used to define the materials 387 
surface properties. TGA was also performed to examine the functionalization degree of the s-GO 388 
sheets. Moreover, XPS was used to examine the composition of the GO sheets, C/O ratio, and the 389 
presence of the different functional groups.  390 
s-GO functionalization. QD have been prepared according to the literature by controlled 391 
decomposition of Ag and In salts. Briefly, 88.4 mg of InCl3 (0.4 mmol, Sigma Aldrich) and 17 mg 392 
AgNO3 (0.1 mmol, Sigma Aldrich) were placed in a 100 ml round-bottom flask. Then, 190 µL of 393 
oleic acid (0.6 mmol, Sigma Aldrich), 720 µL dodecylthiol (0.6 mmol, Sigma Aldrich) and 394 
8 mL of 1-octadecene (Sigma Aldrich) have been added under argon. The solution was heated at 395 
60 °C for 15 min, at 90 °C for 15 min, and left at 110 °C stirring till no precipitate was visible (15-396 
30 min). Then, 4 mL of solution S (9.6 mg 0.3 mmol, Sigma Aldrich) was added and the mixture 397 
turned reddish. Finally, 5 mL of ZnCl2 solution (70.5 mg 0.5 mmol, Sigma Aldrich) in oleylamine 398 
and 1-octadecene were added and the temperature was raised to 150 °C. After 15 min, the reaction 399 
was cooled with an ice bath. The QDs were purified by precipitation with ethanol, re-suspended 400 
with cyclohexane, washed several times with ethanol/acetone and stored in CH2Cl2. For the water 401 
transfer reaction, 2 mL of solution oil QDs (2 mg/mL dispersion) have been added to 1 mL of a 402 
cysteine (50 mg 0.4 mmol) basic solution in methanol. Immediately, the QD precipitated. After 20 403 
min, 5 mL of distilled water have been added and the QD passed throw the aqueous phase. 404 
Subsequently, the water soluble QDs have been precipitated with acetone, washed several times 405 
with acetone/ethanol and stored in distilled water. For GO conjugation QDs have been mixed with 406 
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GO (1 mg/mL) at 1/10 mass ratio in distilled water. The mixture has been left stirring for 3 days 407 
and then purified via dialysis against distilled water. 408 
Preparation of hippocampal cultures and acute hippocampal slices. Primary hippocampal 409 
cultures were prepared from neonatal rats at 2-3 postnatal days (P2-P3) as previously 410 
reported.10,26,62 All procedures were approved by the local veterinary authorities and performed in 411 
accordance with the Italian law (decree 26/14) and the UE guidelines (2007/526/CE and 412 
2010/63/UE). The animal use was approved by the Italian Ministry of Health. All efforts were 413 
made to minimize suffering and to reduce the number of animals used. All chemicals were 414 
purchased by Sigma-Aldrich unless stated otherwise. Cultures were then used for experiments 415 
after 8 ÷ 12 days in vitro. Hippocampal acute slices were obtained from P7-P8 rats and from 416 
juvenile P15 rats (n = 18 animals) using a standard protocol.63,64  417 
Electrophysiological recordings. In dissociated hippocampal cultures, single and paired whole-418 
cell recordings were obtained with pipettes (5-7 MΩ) with the following intracellular saline 419 
solution (in mM): 120 K gluconate, 20 KCl, 10 HEPES, 10 EGTA, 2 MgCl2, 2 Na2ATP, pH 7.3; 420 
osmolarity 300 mOsm. The extracellular saline contained (in mM) 150 NaCl, 4 KCl, 1 MgCl2, 2 421 
CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, pH 7.4. Data were recorded by Multiclamp 700B patch 422 
amplifier (Axon CNS, Molecular Devices) digitized at 10 KHz by pClamp 10.2 software 423 
(Molecular Devices LLC, USA). Basal PSCs were recorded at − 56 mV holding potential (liquid 424 
junction potential of 14 mV was not corrected for). mPSCs were recorded in the presence of TTX 425 
(1 μM) to block fast voltage-dependent sodium channels. In voltage-clamp recordings, PSCs and 426 
mPSCs were detected by the use of the AxoGraph X (Axograph Scientific) event detection 427 
program and by the Clampfit 10 software (pClamp suite, Axon Instruments) as previously 428 
reported64. On average, ≥ 500 PSCs were analyzed from each cell and from the average of these 429 
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events we measured the peak amplitude and the decay time constant (expressed as τ) by fitting a 430 
mono-exponential function. In paired recordings, the presynaptic neuron in current clamp mode 431 
was held at −70 mV (by ≤ 0.02 nA negative current injection), and action potentials were evoked 432 
by delivering short (4 ms) square current pulses (1 nA). Monosynaptic connections were identified 433 
by their short delay (< 2 ms)64. To characterize the short-term dynamics of synaptic contacts, we 434 
delivered, to pairs of connected neurons, paired pulse stimulations at 20 Hz (1 pair every 20 s; 10 435 
times, that were pooled together and averaged). For acute hippocampal slices, a patch-clamp 436 
amplifier (Multiclamp 700B, Axon Instruments, Sunnyvale, CA, USA) allowed recordings from 437 
CA1 pyramidal neurons, identified by visual inspection at an upright microscope (Eclipse FN1; 438 
Nikon, Japan) equipped with differential interference contrast optics and digital videocamera 439 
(Nikon, Japan). All recorded events were analyzed offline with the AxoGraph 1.4.4 (Axon 440 
Instrument) event detection software (Axon CNS, Molecular Devices). s-GO was acutely 441 
delivered10, both in dissociated cells and in acute hippocampal slices, by an injection of pressurized 442 
air (500 ms duration, 8 PSI; by a Picospritzer PDES-02DX; NPI electronic GmbH, Germany). 443 
Once patch-clamped neurons, a second pipette identical to that used for patch-clamp recording, 444 
was positioned at a distance of 200 μm (under microscopy control) from the recorded cell. The 445 
pipette was filled with standard saline solution (control; osmolarity 300 mosmol l-1) or with s-GO, 446 
l-GO and us-GO (100 μg/mL in Krebs solution; osmolarity 300 mosmol l-1). The concentration of 447 
GO reaching the cell was at least 10 % of that contained in the pipette, considering 1 mL of 448 
extracellular solution in the recording chamber. Baseline PSCs were sampled before (10 min) and 449 
after (10 min) the local ejection. Analyses were performed between 4 min and 8 min after the local 450 
ejection, sampling 2 min of recordings. 451 
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Confocal microscopy in hippocampal cultures. Cultured hippocampal neurons (3 cultures; 6-8 452 
DIV) were incubated for 30 minutes with s-GO (20 μg/mL). Cultures were then fixed by 4 % 453 
formaldehyde (prepared from fresh paraformaldehyde; Sigma) in PBS at RT and blocked and 454 
permeabilized in 5 % fetal bovine serum (FBS), 0.3 % Triton-X 100 in PBS for 30 min at RT. 455 
Samples were incubated with primary antibodies (mouse monoclonal anti-bassoon, 1:400 dilution; 456 
rabbit anti-β-tubulin III, 1:500 dilution) diluted in PBS with 5 % FBS for 45 minutes. Cultures 457 
were finally incubated with secondary antibodies (Alexa 488 goat anti-mouse, Invitrogen, 1:500 458 
dilution; Alexa 594 goat anti-rabbit, Invitrogen, 1:500 dilution) and DAPI (Invitrogen, dilution 459 
1:200) to stain the nuclei, for 45 minutes at RT and finally mounted on 1 mm thick glass coverslips 460 
using the Fluoromount mounting medium (Sigma-Aldrich). To visualize s-GO localization was 461 
used the reflection mode of confocal microscopy.58 Images were acquired using a Nikon C2 462 
Confocal, equipped with Ar/Kr, He/Ne and UV lasers. Images were acquired with a 60 × (1.4 NA) 463 
oil-objective (using oil mounting medium, 1.515 refractive index). Confocal sections were 464 
acquired every 0.4 μm. 465 
Surgery and s-GO injection. Four experimental groups were used: standard saline solution 466 
(control) and s-GO 50 μg/mL injection, analyzed at 48 h and 72 h. Surgery was performed in P15 467 
Wistar rats anesthetized with ketamine (60 mg/kg i.p.) and xylazine (10 mg/kg i.p.). All animal 468 
procedures were conducted in accordance with the National Institutes of Health, international and 469 
institutional standards for the care and use of animals in research, and after consulting with a 470 
veterinarian. All experiments were performed in accordance with the EU guidelines (2010/63/UE) 471 
and Italian law (decree 26/14) and were approved by the local authority veterinary service. All 472 
efforts were made to minimize animal suffering and to reduce the number of animal used. The 473 
Italian Ministry of Health, in agreement with the EU Recommendation 2007/526 /CE, approved 474 
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animal use (authorization n° 1135/2015-PR). Animals were fixed in a stereotaxic device (World 475 
Precision Instruments, WPI). An incision was made on the top of the head in order to expose the 476 
skull and identify bregma and lambda coordinates. The injection of 1 μL of saline or s-GO solution 477 
(10 steps of 0.1 μL every minute) was performed with a Hamilton syringe (26s gauge; Hamilton). 478 
The following coordinates were used to reach the left dentate gyrus: AP: -3.0, ML: -3.0, DV: -3.3 479 
relative to bregma.65 At the end of the last step, the syringe was left in situ for extra 5 minutes to 480 
optimize the solution permeation. The incision was sutured and animals were constantly monitored 481 
and left undisturbed until electrophysiological or histological experiments.  482 
Histology procedures. After 48 h or 72 h, animals were anesthetized and sacrificed by intracardiac 483 
perfusion with 0.1 M PBS followed by 4 % formaldehyde (prepared from fresh paraformaldehyde; 484 
Sigma) in PBS. Brains were promptly removed, postfixed in the same fixative solution for 24 h at 485 
4 °C, and cryoprotected in 30 % sucrose in PBS at 4 °C for 24-48 h. Finally, brains were embedded 486 
in optimal cutting temperature (OCT) compound (Tissue-Tek), frozen at – 20 °C, and sagittal 487 
sections (25 μm) were obtained using a cryostat (Microm HM 550, Thermo Fisher Scientific) and 488 
processed for immunohistochemistry. Tissue-Tek was removed by PBS washing and tissue 489 
sections were protein-blocked in 3 % BSA, 3 % FBS and 0.3 % Triton X-100 in PBS for 45 minutes 490 
at RT. Sections were then incubated overnight at 4 °C with primary antibodies (mouse anti-GFAP, 491 
Sigma-Aldrich, 1:400; rabbit anti-Iba1, Wako, 1:500; rabbit anti-β-tubulin III, Sigma-Aldrich, 492 
1:500; mouse anti-Bassoon, Abcam, 1:400) in 5 % FBS in PBS. After washing in PBS, sections 493 
were incubated in secondary antibodies (goat anti-rabbit AlexaFluor 594, Thermo Fisher 494 
Scientific, 1:400; goat anti-mouse AlexaFluor 488, Thermo Fisher Scientific, 1:400) in 5% FBS 495 
in PBS for 2-4h at RT. Nuclei were labeled with DAPI (Thermo Fisher Scientific, 1:500) in PBS 496 
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for 20-30 minutes at RT. Upon final washing (PBS and water), tissue sections were mounted on 497 
glass coverslips using Vectashield mounting medium (Vector Laboratories). 498 
Image acquisition and analysis. We measured the brain tissue reaction by markers for reactive 499 
astrocytes and microglia (GFAP and Iba1, respectively). Fluorescence images were acquired using 500 
a Leica DM6000 upright microscope with a 10 × dry objective. Identical binning, gains and 501 
exposure times were used for all images of the same marker. Image analysis was performed using 502 
Fiji software. For both GFAP and Iba1 intensity measurements, a single region of interest (ROI, 503 
1000 × 500 μm2) was selected at the injection site (left dentate gyrus). The background intensity 504 
threshold was defined for each section using the labeling intensity measured in the contralateral 505 
hemisphere in the same anatomical region (right dentate gyrus). The area within each ROI with 506 
intensity above the background threshold was calculated, normalized to the contralateral 507 
hemisphere and used for statistics. The ROI for all sections were averaged for each experimental 508 
group. We performed this analysis also 300 μm medial and lateral to the injection site. We 509 
visualized s-GO by linking QD. Fluorescence images were acquired using a Leica DM6000 510 
upright microscope with a 10 × dry objective. We further analyzed the amount of synaptic contacts 511 
by a specific marker for synapses (bassoon) in two experimental groups: saline and s-GO injection 512 
at 48 h. Confocal images were acquired using a confocal microscope (Nikon C1) with a 60 × oil 513 
objective (N.A. 1.4, oil mounting medium refractive index 1.515). Z-stacks were acquired every 514 
350 nm for a total thickness of 7 μm. Identical binning, gain and exposure time was used for all 515 
images. 9 ROIs (70 × 70 μm2) for each section were randomly selected at the injection site (left 516 
dentate gyrus). Offline analysis was performed using Volocity software (Volocity 3D image 517 
analysis software, PerkinElmer, USA). For each ROI, we used the Z-stack to quantify bassoon 518 
signal as 3D objects. From the resulting values, we calculated the volume of only bassoon objects 519 
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co-localized with the β-tubulin III labeling in order to identify genuine synapses at neuronal level. 520 
The ROI for all sections were pooled together and averaged for each experimental group.  521 
Raman mapping of brain sections. Raman mapping of sectioned brain samples was completed 522 
using a DXRi Raman Mapping system (Thermo Scientific, USA) using the following conditions: 523 
ʎ = 633 nm, 1 mW, pixel size = 1.6 μm and frequency = 25 Hz. The maps were generated according 524 
to the composite spectra’s percentage similarity to a correlation GO spectral reference as shown. 525 
Statistical analysis. All values from samples subjected to the same experimental protocols were 526 
pooled together and results are presented as mean ± S.D., if not otherwise indicated; n = number 527 
of neurons, if not otherwise indicated. Statistically significant difference between two data sets 528 
was assessed by Student’s t-test for parametric data. Differences between the logarithmic values 529 
of the analyzed variables were assessed using two-way ANOVA and multiple comparisons were 530 
adjusted by Bonferroni or Holm-Sidak correction. Statistical significance was determined at P < 531 
0.05, unless otherwise indicated. Significance was graphically indicated as follows: *P < 0.05, **P 532 
< 0.01,***P < 0.001. 533 
  534 
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 535 
Figure 1. Characterization of s-GO. (a) AFM measure of s-GO sheets. (b) s-GO lateral 536 
dimension distribution. (c) S-GO Raman spectrum. (d) XPS survey of QD-s-GO. UV-vis (e) and 537 
fluorescence (f) spectra of s-GO, QD and QD-s-GO. 538 
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Figure 2. s-GO affects presynaptic glutamate release in hippocampal cultures (a) Sketch of the 540 
experimental setting for simultaneous s-GO pressure-release (puff) and single-cell recording 541 
from cultured neurons. (b) Top: diagram of the experimental protocol. Bottom: representative 542 
tracings of the spontaneous synaptic activity detected prior and after puff applications of control 543 
saline (Control, top) or s-GO (bottom). Recordings of mEPSCs are performed in the presence of 544 
TTX. In (c) bar plots of pooled data summarize the average mEPSCs frequency (left) and 545 
amplitude (right) before (PRE puff) and after (Washout) saline (Control) or s-GO (100 μg/mL 546 
final concentration) pressure ejections (* P < 0.05 Student’s t-test). Note the reversible increase 547 
in miniatures frequency due to s-GO. In (d) simultaneous pair recordings are shown: top traces 548 
represent presynaptic pairs (30 Hz) of action potentials, bottom ones the corresponding evoked 549 
monosynaptic PSCs (GABAA-receptor mediated on the left and glutamate AMPA-receptor 550 
mediated on the right) prior and after s-GO puffs. The paired-pulse ratios (PPR) measured prior 551 
and after saline solution (Control) and s-GO puffs are summarized in the histograms; note that s-552 
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GO reduced the first evoked AMPA-receptor mediated PSCs and the PPR of glutamatergic 553 
synapses (*P < 0.05 Student’s t-test) supporting the notion of s-GO affecting presynaptic release. 554 
  555 
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 557 
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Figure 3. EPSCs frequency modulation by s-GO in hippocampal slices in vitro and in vivo (a) 558 
Sketch of the experimental setting for simultaneous s-GO release and recording from 559 
hippocampal pyramidal cells. In (b) top: diagram of the experimental protocol. Bottom: 560 
representative current tracings recorded prior and after saline (Control; top) and s-GO (bottom) 561 
local pressure ejections. Glutamate AMPA-receptor mediated PSCs or GABAA-receptor 562 
mediated ones (EPSCs and IPSCs, respectively) were pharmacologically isolated and bar plots in 563 
(c) summarize the mean values of EPSCs and in (d) of IPSCs frequency before and after saline 564 
(Control) or s-GO puffs (*P < 0.05 Student’s t-test). Note that also in hippocampal slice explants 565 
only glutamatergic activity was transiently affected by brief local injection of s-GO. In (e) plots 566 
of pooled data represent the average PSCs frequency upon 30 min, 45 min, 3 h and 6 h s-GO 567 
incubation (50 μg/mL final concentration; Control: blue circles; s-GO: red squares). Note that 568 
prolonged incubation in s-GO depresses spontaneous synaptic activity. Linear regression 569 
analysis of the two time progressions is depicted as blue and red fitting lines (y = 4.91+0.11x for 570 
Control and y = 5.56-0.74x for s-GO, respectively) together with their corresponding confidence 571 
interval in pale blue and pale red, respectively. Regardless the significance of the difference 572 
between each two conditions at a specific time point (at 30 m P = 0.91, at 45 m P = 0.60, at 3 h P 573 
= 0.07, at 6 h P = 0.06), multiple regression statistical analysis revealed that the zero slope 574 
hypothesis is accepted for Controls but not for s-GO. The equal slope hypothesis between the 575 
two trends was instead rejected by a Tukey test on the two slopes. f) In vivo intra-hippocampal s-576 
GO delivery reversibly reduces glutamatergic synaptic activity in adult rats: sketch of the 577 
experimental settings (left) and (right) spontaneous synaptic activity recorded from ex vivo 578 
hippocampal slices isolated from juvenile rats after 48 h from the surgery. Recordings were 579 
taken from the contralateral, control (saline) and s-GO (50 μg/mL final concentration) injected 580 
hemisphere after 48 h from surgery. In (g) bar plots summarize the PSCs and in (h) the EPSCs 581 
frequency in control and s-GO treated animals after 48 h and after 72 h from surgery (**P < 582 
0.001 two-way ANOVA; *P < 0.05 two-way ANOVA). Note that the specific reduction in EPSC 583 
frequency at 48h that was entirely reversed at 72 h. 584 
 585 
 586 
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Figure 4. In vivo delivery of s-GO is localized and does not alter excitatory synaptic density. In 588 
(a) confocal Raman maps were acquired to establish the location of s-GO within cryosectioned 589 
dendate gyrus’ of s-GO (1.3 mg/mL) treated animals over time (48 h and 72 h). Scale bars = 500 590 
nm. Maps were generated based on the acquired spectra's correlation to a s-GO reference spectra, 591 
shown on the right. The dentate gyrus of rats injected with saline (Controls) and rats treated with 592 
a higher concentration (1.3 mg/ mL) (positive control) were also examined for comparison. The 593 
acquisition parameters were as follows λ= 633 nm, laser power = 1 mW, frequency = 25 Hz and 594 
a pixel size of 1.6 μm. In (b) Ex vivo fluorescence imaging of hippocampal slices processed for 595 
Iba1-positive microglia (in green) and QD linked to s-GO (in red) at the injection site after 48 h. 596 
DAPI for nuclei is in blue. Note the precise localization of s-GO within the target area. (c) Ex 597 
vivo confocal images of hippocampal synapses at the injection site, excitatory presynaptic 598 
terminals were identified by the marker bassoon (in green), in neurons co-labeled with β-tubulin 599 
III (in red) and results are shown for saline (control) and s-GO injections after 48 h. DAPI for 600 
nuclei is in blue. Analysis has been performed at the higher magnification on 70 × 70 μm2 ROIs 601 
shown in (d) and results are summarized by the bar plots. No differences in bassoon 602 
quantification were detected between saline and s-GO injection after 48h. Scale bars: 100 μm in 603 
(b), 25 μm in (c) and 10 μm in (d). 604 
 605 
 606 
 607 
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 608 
Figure 5. Brain tissue reactivity to surgery and s-GO injections after 48 h and 72 h. Ex vivo 609 
hippocampal slices from saline (control) and s-GO injected brains were labeled for GFAP-610 
positive astrocytes (in green, top row) and Iba1-positive microglia (in red, bottom row) and the 611 
injection site (left dentate gyrus, saline vs. s-GO 50 μg/mL) are shown after 48 h (A) and 72 h 612 
(B). DAPI for nuclei is in blue. Scale bar: 100 μm.  Bar plots in (C) and (D) quantify the glial 613 
reaction 48 h and 72 h post- surgery. Comparable values of GFAP and Iba1 immunoreactivity 614 
between saline and s-GO were observed in the hippocampus at 300 μm distance from the 615 
injection site, either lateral or medial in both 48 h and 72 h post-surgery. Notably, at the injection 616 
site, s-GO induced lower GFAP immunoreactivity at 48 h and lower Iba1 immunoreactivity at 72 617 
h when compared to controls. (** P < 0.01 two-way ANOVA). 618 
 619 
 620 
 621 
 622 
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